Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors

Taru Muranen, Funda Meric-Bernstam, Gordon Mills

Research output: Contribution to journalShort survey

5 Citations (Scopus)

Abstract

In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted. In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.

Original languageEnglish (US)
Pages (from-to)7-9
Number of pages3
JournalCancer Cell
Volume26
Issue number1
DOIs
StatePublished - Jul 14 2014
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Therapeutics
Breast Neoplasms
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors. / Muranen, Taru; Meric-Bernstam, Funda; Mills, Gordon.

In: Cancer Cell, Vol. 26, No. 1, 14.07.2014, p. 7-9.

Research output: Contribution to journalShort survey

Muranen, Taru ; Meric-Bernstam, Funda ; Mills, Gordon. / Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors. In: Cancer Cell. 2014 ; Vol. 26, No. 1. pp. 7-9.
@article{4915003a83504cca81401ee9ee5dac07,
title = "Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors",
abstract = "In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted. In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.",
author = "Taru Muranen and Funda Meric-Bernstam and Gordon Mills",
year = "2014",
month = "7",
day = "14",
doi = "10.1016/j.ccr.2014.06.020",
language = "English (US)",
volume = "26",
pages = "7--9",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors

AU - Muranen, Taru

AU - Meric-Bernstam, Funda

AU - Mills, Gordon

PY - 2014/7/14

Y1 - 2014/7/14

N2 - In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted. In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.

AB - In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted. In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84904244868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904244868&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2014.06.020

DO - 10.1016/j.ccr.2014.06.020

M3 - Short survey

VL - 26

SP - 7

EP - 9

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -